Abreos Biosciences, a San Diego, CA-based biotech company, completed a new investment round of undisclosed amount.
Backers included existing investors as well as new investor TLP Investment Partners and its affiliates.
The company will use the funds to continue to expand operations and offerings.
Founded in 2013 by Dr. Bradley Messmer, Ph.D., CEO, Abreos Abreos Biosciences focuses on developing technologies for monitoring antibody therapies in blood as well as point-of-care devices for clinical testing.
The Abreos VeritopeTM technology platform allows for the selective monitoring of therapeutic antibody drugs, whether brand name or biosimilars. By monitoring the levels of these therapies, clinicians can optimize therapeutic dose and timing to help achieve optimal response to these expensive therapies.
To date, tests for therapies in four major clinical areas, including autoimmune disease, oncology, neurology, and cardiology, have been developed. These assays include those for rituximab, vendolizumab, adalimumab, pembrolizumab, obinutuzumab, trastuzumab, ipilumumab, natalizumab, and ocrelizumab.